Journal article
Targeted chemoradiation in metastatic colorectal cancer: A phase i trial of 131i-hua33 with concurrent capecitabine
RA Herbertson, NC Tebbutt, FT Lee, S Gill, B Chappell, T Cavicchiolo, T Saunder, GJ O'Keefe, A Poon, ST Lee, R Murphy, W Hopkins, FE Scott, AM Scott
Journal of Nuclear Medicine | Published : 2014
Abstract
huA33 is a humanized antibody that targets the A33 antigen, which is highly expressed in intestinal epithelium and more than 95% of human colon cancers but not other normal tissues. Previous studies have shown huA33 can target and be retained in a metastatic tumor for 6 wk but eliminated from normal colonocytes within days. This phase I study used radiolabeled huA33 in combination with capecitabine to target chemoradiation to metastatic colorectal cancer. The primary objective was safety and tolerability of the combination of capecitabine and 131I-huA33. Pharmacokinetics, biodistribution, immunogenicity, and tumor response were also assessed. Methods: Eligibility included measurable metastat..
View full abstractGrants
Awarded by National Health and Medical Research Council of Australia
Awarded by NIH
Funding Acknowledgements
The costs of publication of this article were defrayed in part by the payment of page charges. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734. This study was supported, in part, by National Health and Medical Research Council of Australia grants 280912 and 487922, NIH R21 CA108145-01A1, and the Ludwig Institute for Cancer Research and by funds from the Operational Infrastructure Support Program provided by the Victorian Government, Australia. This study was conducted with full compliance with current laws of Australia and with approval of the Human Research Ethics Committee of the Austin Hospital, Melbourne, Australia, and the Protocol Review Committee, Ludwig Institute for Cancer Research, New York, New York. No other potential conflict of interest relevant to this article was reported.